ArticleInternational journal of hepatology2026
The Five-Time Chair Stand Test Identifies Patients With Liver Cirrhosis at High Mortality Risk Overlooked by Conventional Sarcopenia Criteria.
Article in International journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is a major complication of liver cirrhosis (LC), but current Japan Society of Hepatology (JSH) criteria are based on muscle mass and strength and do not incorporate physical performance. We investigated whether the five-time chair stand test (5T-CST) identifies high-risk patients not detected by conventional sarcopenia assessment. Methods: We retrospectively analyzed 241 patients with LC who underwent the 5T-CST. Low physical performance was defined as a 5T-CST time ≥ 12 s. Patients were classified according to their handgrip strength and physical performance, with focus on those with normal handgrip strength. Results: Longer 5T-CST duration was associated with lower handgrip strength and sarcopenia, but not low skeletal muscle mass index. Among 151 patients with normal handgrip strength and survival data, 27 (17.9%) had low physical performance. This subgroup had preserved muscle mass but more ascites and hepatic reserve impairment and lower survival (mortality, 29.6% vs. 12.1%; log-rank Conclusions: Among patients with LC and normal handgrip strength, the 5T-CST identified a subgroup at a high risk of mortality. Adding this simple test to sarcopenia assessment may help identify patients otherwise missed by handgrip strength alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.